Article Details

Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an ...

Retrieved on: 2021-06-14 14:26:15

Tags for this article:

Click the tags to see associated articles and topics

Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an .... View article details on hiswai:

Excerpt

Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment.

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up